Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

INBX holding history

Inhibrx Biosciences, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

INBX overviewAll 13F holders of INBXFull Q2 2026 holdings

Shares (Q2 2026)
35,019
Value
$3.32M
% of portfolio
<0.1%
Quarters held
19
Since Q1 2021
Holdings of INBX by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202635,019$3.32M<0.1%−13,118−27.3%ReducedHolders
Q1 202648,137$3.24M<0.1%−25,562−34.7%ReducedHolders
Q4 202573,699$5.82M<0.1%+64,273+681.9%AddedHolders
Q3 20259,426$317.5K<0.1%−36,558−79.5%ReducedHolders
Q2 202545,984$656.2K<0.1%+18,516+67.4%AddedHolders
Q1 202527,468$384.3K<0.1%+9,711+54.7%AddedHolders
Q4 202417,757$273.5K<0.1%+11,716+193.9%AddedHolders
Q3 20246,041$94.6K<0.1%+2,836+88.5%AddedHolders
Q2 20243,205$45.4K<0.1%−441,992−99.3%ReducedHolders
Q1 2024445,197$15.6M<0.1%+364,412+451.1%AddedHolders
Q4 202380,785$3.07M<0.1%+42,782+112.6%AddedHolders
Q3 202338,003$697.4K<0.1%+36,192+1,998.5%AddedHolders
Q2 20231,811$47.0K<0.1%−47,171−96.3%ReducedHolders
Q1 202348,982$924.3K<0.1%−40,265−45.1%ReducedHolders
Q4 202289,247$2.20M<0.1%+71,452+401.5%AddedHolders
Q3 202217,795$319.0K<0.1%+17,795NewHolders
Q2 20220$00.0%−32,343−100.0%Sold outHolders
Q1 202232,343$721.0K<0.1%−4,615−12.5%ReducedHolders
Q4 202136,958$1.61M<0.1%+36,958NewHolders
Q2 20210$00.0%−2,522−100.0%Sold outHolders
Q1 20212,522$51.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.